225220.KQ Genolution Inc.
- Market cap
- KRW 31.2B
- P/E
- -
- P/B
- 0.45x
- ROE
- 3.9%
- Dividend yield
- -
- Fundamental score
- 0.7/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 225220.KQ undervalued?
Graham numberThe Graham number of Genolution Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genolution Inc. fundamental analysis
4 of 22 checks passedROE 0/2
Low return on equity (3.9%), below 10%.
ROA 1/1
Return on assets (2.9%) is above the industry median (-10.1%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-70.4%) is below the industry median (4.8%).
Revenue Growth 0/2
Revenue shrank 37.3% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Debt is not reported.
Interest Coverage 0/1
EBIT is 3.4x against interest expense, below 5x.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (0.4x) is below the industry median (2.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Genolution Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genolution Inc.
Genolution Inc. manufactures and sells IVD medical instruments in South Korea and internationally. Its products are primarily focused on molecular diagnostics, ribonucleic acid interference (RNAi) services, and double-stranded RNA (dsRNA) synthesis technology. The company offers Nextractor NX-Duo, Nextractor NX-32N/45N, Nextractor NX-Jr, Nextractor NX-24SA, NGS library preparation equipment, DNA/RNA extraction kits. It also develops and manufactures instruments and reagents …
Full company profileGenolution Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Genolution Inc. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.50B | 2.44B | 3.13B | 3.95B | 85.3B | 72.8B | 38.1B | 9.76B | 7.14B | 9.40B | 11.2B |
| Gross Profit | 1.23B | 1.89B | 2.29B | 2.60B | 63.3B | 53.4B | 26.4B | 4.52B | 2.37B | 3.53B | 4.00B |
| Operating Income | 78.0M | 628M | 183M | 148M | 54.0B | 41.3B | 15.0B | -8.14B | -9.49B | -8.64B | -5.95B |
| EBITDA | - | - | - | - | - | - | 18.9B | -5.51B | -4.31B | -9.35B | 3.68B |
| Net Income | 88.1M | 577M | 1.29B | -287M | 32.0B | 34.4B | 14.6B | -5.55B | -6.83B | -11.6B | 2.75B |
| EPS | 16 | 99 | 203 | -48 | 3,350 | 1,881 | 809 | -307 | -378 | -644 | 152 |
| Balance Sheet | |||||||||||
| Total Assets | 3.99B | 4.71B | 11.1B | 13.4B | 83.8B | 94.9B | 114B | 113B | 106B | 93.8B | 94.6B |
| Total Liabilities | 571M | 704M | 8.16B | 10.8B | 22.5B | 12.7B | 19.8B | 26.0B | 26.2B | 25.9B | 25.8B |
| Shareholders' Equity | 3.42B | 4.00B | 2.94B | 2.64B | 61.3B | 82.2B | 94.7B | 87.4B | 80.3B | 68.4B | 69.8B |
| Cash & Short-term Investments | 2.33B | 2.15B | 5.22B | 3.82B | 49.0B | 45.9B | 46.4B | 42.8B | 33.2B | 18.8B | 18.6B |
| Total Debt | - | - | 1.64B | 3.55B | 6.65B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -27.0M | 717M | 147M | -80.6M | 46.0B | 25.7B | 13.6B | -1.14B | -1.43B | -7.01B | -2.73B |
| Capital Expenditure | 356M | 862M | 2.92B | 3.14B | 8.68B | 5.13B | 22.5B | 6.88B | 12.2B | 443M | 489M |
| Free Cash Flow | - | - | - | -4.72B | 36.4B | 20.6B | -8.99B | -8.02B | -13.6B | -7.45B | -3.22B |
| Ratios | |||||||||||
| ROE | 2.6% | 14.4% | 44.0% | -10.9% | 52.3% | 41.8% | 15.4% | -6.3% | -8.5% | -17.0% | 3.9% |
| ROA | 2.2% | 12.3% | 11.6% | -2.1% | 38.3% | 36.2% | 12.8% | -4.9% | -6.4% | -12.4% | 2.9% |
| Net Profit Margin | 5.9% | 23.7% | 41.3% | -7.3% | 37.6% | 47.2% | 38.3% | -56.9% | -95.7% | -123.8% | 24.6% |
| Debt to Equity | - | - | 0.56x | 1.35x | 0.11x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Genolution Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Dec 29, 2021
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | KRW 1.81B | 100 | 12.4% |
| 2021 | KRW 5.23B | 286 | 15.2% |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Apr 19, 2023.
Who owns Genolution Inc.
- Insiders 27.62%
- Institutions 0.00%
- Public & others 72.38%
- Shares outstanding 18.1M
- Free float 12.5M
Genolution Inc. company profile
- Company name
- Genolution Inc.
- Ticker
- 225220.KQ
- ISIN
- KR7225220003
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 72
- Fiscal year end
- December
- Address
- 63 Magokjungang 8-ro 3-gil, Seoul, South Korea, 05836
- Phone
- 82 2 449 8670
- Website
- genolution.co.kr
About Genolution Inc.
Genolution Inc. manufactures and sells IVD medical instruments in South Korea and internationally. Its products are primarily focused on molecular diagnostics, ribonucleic acid interference (RNAi) services, and double-stranded RNA (dsRNA) synthesis technology. The company offers Nextractor NX-Duo, Nextractor NX-32N/45N, Nextractor NX-Jr, Nextractor NX-24SA, NGS library preparation equipment, DNA/RNA extraction kits. It also develops and manufactures instruments and reagents for DNA/RNA; provides long dsRNA synthesis services; and siRNA/miRNA/shRNA synthesis service and related products. Genolution Inc. was founded in 2006 and is based in Seoul, South Korea.
Genolution Inc. management
6- Mr. Ki-Ok KimCo-CEO & Representative Director · born 1955
- Ms. MinYi Kim Ph.D.Co-CEO & Representative Director · born 1986
- Mr. Sanghun KimChief Financial Officer · born 1960
- Mr. WooJin KimManaging Director · born 1969
- Mr. SunShin LeeManaging Director · born 1961
- Mr. JungHoon ParkManaging Director · born 1974